Charakopoulos Emmanouil, Spyrou Ioannis, Viniou Nora-Athina, Giannakopoulou Nefeli, Hatzidavid Sevastianos, Diamantopoulos Panagiotis Theodorou
Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Medicine (Baltimore). 2020 May 22;99(21):e20048. doi: 10.1097/MD.0000000000020048.
Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first authors to report a case of Hodgkin lymphoma in a psoriatic patient receiving ustekinumab.
A 22-year-old asymptomatic female patient presented to our department to investigate an enlarged cervical lymph node. Her past history was unremarkable, except for psoriasis since age 13. Two months before presentation the decision to administer Ustekinumab was taken and the patient had already received 3 doses.
During workup a Stage IV Hodgkin lymphoma was discovered.
Ustekinumab administration was discontinued. The patient received treatment with the ABVD regimen.
The patient's disease was refractory to the above-mentioned treatment. Therefore, a more aggressive regimen (BEACOPP escalated) was administered.
Growing postmarketing surveillance data and case reports indicate that further research is warranted in order to elucidate a potential association between Ustekinumab and malignancy.
乌司奴单抗是一种抑制白细胞介素12和23的生物制剂，已被批准用于治疗中度和重度斑块状银屑病。有病例报告引发了对其致癌潜力的担忧。我们是首例报告接受乌司奴单抗治疗的银屑病患者发生霍奇金淋巴瘤病例的作者。
一名22岁无症状女性患者因颈部淋巴结肿大前来我科就诊。除13岁起患银屑病外，她既往史无异常。就诊前两个月决定使用乌司奴单抗，患者已接受3剂治疗。
检查期间发现IV期霍奇金淋巴瘤。
停用乌司奴单抗。患者接受ABVD方案治疗。
患者的疾病对上述治疗无效。因此，给予了更积极的方案（强化BEACOPP方案）。
越来越多的上市后监测数据和病例报告表明，有必要进行进一步研究以阐明乌司奴单抗与恶性肿瘤之间的潜在关联。
